Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma
Gilead has forged the big, transformational buyout deal that everyone in the industry has been waiting for.
The buyout will instantly make Gilead a leader in adoptive cell therapy, going head-to-head against Novartis’ leading effort with CTL019. And in a call with analysts early Monday, Gilead execs underscored that while cell therapies would become the cornerstone of their work in oncology, the business development team is pursuing more pacts to build that segment of the pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.